Proof-of-concept study of compartmentalized lung ventilation using system for asymmetric flow regulation (SAFR).

Autor:	Barjaktarevic I; Division of Pulmonary and Critical Care Medicine, University of California Los Angeles, CA, United States., Meyerowitz G; UCLA Biodesign, University of California Los Angeles, Los Angeles, California, CA, United States., Williams O; UCLA Biodesign, University of California Los Angeles, Los Angeles, California, CA, United States., Emeruwa IO; Division of Pulmonary and Critical Care Medicine, University of California Los Angeles, CA, United States.; UCLA Biodesign, University of California Los Angeles, Los Angeles, California, CA, United States., Hoftman N; Department of Anesthesiology, University of California Los Angeles, CA, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in medical technology [Front Med Technol] 2023 Mar 30; Vol. 5, pp. 1121674. Date of Electronic Publication: 2023 Mar 30 (Print Publication: 2023).
DOI:	10.3389/fmedt.2023.1121674
Abstrakt:	Asymmetrical distribution of acute lung injury in mechanically ventilated patients can result in a heterogeneity of gas distribution between different regions, potentially worsening ventilation-perfusion matching. Furthermore, overdistension of healthier, more compliant lung regions can lead to barotrauma and limit the effect of increased PEEP on lung recruitment. We propose a System for Asymmetric Flow Regulation (SAFR) which, combined with a novel double lumen endobronchial tube (DLT) may offer individualized lung ventilation to the left and right lungs, better matching each lung's mechanics and pathophysiology. In this preclinical experimental model, the performance of SAFR on gas distribution in a two-lung simulation system was tested. Our results indicate that SAFR may be a technically feasible and potentially clinically useful although further research is warranted. Competing Interests: IB and GM report patent proposal for SAFR (PCT Application No. PCT/US21/58789). IB, GM, OW and OE received the UCLA Innovation Fund support for the development of SAFR. IB also reports research funding from Theravance, Viatris and Aerogen and consulting for Astra Zeneca, Grifols, Inhibrx, Takeda, Sanofi, Verona Pharam, none related to this work. GM, OE, OW and NH have no additional conflicts to report. (© 2023 Barjaktarevic, Meyerowitz, Williams, Emeruwa and Hoftman.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu